Education
About Us
Working with TipRanks
Follow Us
AbSci (ABSI)
NASDAQ:ABSI
ABSI Stock Chart & Stats
$3.03
$0.12(3.91%)
At close: 4:00 PM EST
$3.03
$0.12(3.91%)
Day’s Range― - ―
52-Week Range$2.01 - $6.33
Previous CloseN/A
Volume51.94M
Average Volume (3M)4.23M
Market Cap
$457.13M
Enterprise Value$274.46M
Total Cash (Recent Filing)$152.47M
Total Debt (Recent Filing)$6.22M
Price to Earnings (P/E)―
Beta2.37
Next Earnings
Mar 24, 2026EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.20
Shares Outstanding150,371,540
10 Day Avg. Volume3,410,206
30 Day Avg. Volume4,234,833
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)1.61
Price to Sales (P/S)63.70
P/FCF Ratio-3.97
Enterprise Value/Market Cap0.60
Enterprise Value/Revenue97.50
Enterprise Value/Gross Profit-5.38
Enterprise Value/Ebitda-2.64
Forecast
1Y Price Target
$8.25Price Target Upside172.28% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.83
Revenue Forecast (FY)$4.03M
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentAbsci has made the strategic decision to focus resources on accelerating clinical development of ABS-201, aiming to capture market demand quickly.
Market PotentialRetrospective analysis on androgenetic alopecia hints at blockbuster potential for ABS-201, indicating a significant opportunity in the market.
Strategic PartnershipsManagement continues to anticipate that at least one partnership will be signed with a large pharma company, which could enhance development opportunities.
Bears Say
Product DevelopmentABS-101 will not be advanced internally past Phase 1 due to its shortcomings in efficacy compared to second-generation agents.
Side EffectsExisting treatments like minoxidil and finasteride come with various side effects such as irritation, dandruff, brittle hair, low blood pressure, and sexual dysfunction.
Treatment ComplianceCompliance with current treatments is often poor, which undermines outcomes and highlights challenges in patient adherence.
AbSci News
ABSI FAQ
What was AbSci’s price range in the past 12 months?
AbSci lowest stock price was $2.01 and its highest was $6.33 in the past 12 months.
What is AbSci’s market cap?
AbSci’s market cap is $457.13M.
When is AbSci’s upcoming earnings report date?
AbSci’s upcoming earnings report date is Mar 24, 2026 which is in 110 days.
How were AbSci’s earnings last quarter?
AbSci released its earnings results on Nov 12, 2025. The company reported -$0.2 earnings per share for the quarter, beating the consensus estimate of -$0.205 by $0.005.
Is AbSci overvalued?
According to Wall Street analysts AbSci’s price is currently Undervalued.
Does AbSci pay dividends?
AbSci does not currently pay dividends.
What is AbSci’s EPS estimate?
AbSci’s EPS estimate is -0.18.
How many shares outstanding does AbSci have?
AbSci has 150,371,540 shares outstanding.
What happened to AbSci’s price movement after its last earnings report?
AbSci reported an EPS of -$0.2 in its last earnings report, beating expectations of -$0.205. Following the earnings report the stock price went down -22.353%.
Which hedge fund is a major shareholder of AbSci?
Currently, no hedge funds are holding shares in ABSI
AbSci Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.25 (172.28% Upside)
$8.25 (172.28% Upside)
Blogger Sentiment
Neutral
ABSI Sentiment 50%
Sector Average 68%
Sector Average 68%
Insider Transactions
Bought Shares
Worth $281.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 2.2%
Last 30 Days ▼ 0.8%
Last 30 Days ▼ 0.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-0.32%
12-Months-Change
Fundamentals
Return on Equity
-55.68%
Trailing 12-Months
Asset Growth
4.15%
Trailing 12-Months
Company Description
AbSci
Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.
ABSI Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted Absci Corporation's strategic focus on expanding its pipeline and leveraging its AI platform for drug discovery. Significant progress was made in the development of ABS-201, with promising market opportunities in AGA and endometriosis. Despite challenges with ABS-101, the company remains financially robust and anticipates new partnerships, indicating a positive outlook.View all ABSI earnings summariesABSI Stock 12 Month Forecast
Average Price Target
$8.25
▲(172.28% Upside)
Technical Analysis
Autolus Therapeutics
―
RAPT Therapeutics
―
ADC Therapeutics
―
4D Molecular Therapeutics
―
Design Therapeutics
―
Ownership Overview
7.90% Insiders
20.32% Mutual Funds
11.90% Other Institutional Investors
42.51% Public Companies and Individual Investors